Building the biopharma company of the future

Developing New Categories of Medicine

Our goal is to improve and extend the lives of patients through the development of new categories of medicine

Exploring the Brain Immune Gut (BIG) Axis

Focused on the crosstalk and biological processes associated with the brain-immune-gut interface

Giving Life to Science

Our goal is to improve and extend the lives of patients

Moving Medicine Forward

Discovery Reinvented

Publications
Publications -2017-09-19
Gamma Delta T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation

CD4(+) T regulatory cells (T(regs)), which express the Foxp3 transcription factor, play a critical role in the maintenance of immune homeostasis. Here, we show that in mice, T(regs) were most abundant in the colonic mucosa.

Full Article

Publications -2017-09-19
The Gut’s Clostridium Cocktail

Specific components of the microbiota—the microorganisms that normally colonize the body—can affect disease progression in mouse models of arthritis, central nervous system inflammation, diabetes, intestinal inflammation, and obesity.

Full Article
Publications -2017-06-01
Video game training enhances cognitive control in older adults

Cognitive controlis defined by a set of neural processes that allow us to interact with our complex environment in a goal-directed manner.

FULL ARTICLE

Events
2017-11-17
PureTech’s CEO Daphne Zohar to present in keynote session at CNS Summit 2017 on November 17, 2017, plus Akili’s Eddie Martucci and Adam Gazzaley also to present at conference
Press releases
2017-11-09
PureTech Health to Present at Jefferies 2017 Healthcare Conference in London

PureTech Health plc (LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, today announced that Eric Elenko, PhD, Chief of Research and Strategy at PureTech Health, will present at the Jefferies 2017 Global Healthcare Conference in London on Thursday, 16 November, at 8.00AM GMT. 

Continue

Media Coverage
2017-11-08
Don't Have a Chief Innovation Officer? Get One...Now

Chief innovation officers (CInOs) are poised to become one of the more important executives in the C-suite in pharma just as they are in other industries. As the scope and pace of changes facing the life sciences industry accelerate, innovation must occur faster — not just in R&D but throughout the organization. Achieving fast, focused innovation, however, often requires thinking outside the usual silos and chains of command to foster — and manage — innovation in unusual ways.

FULL ARTICLE